齐拉西酮联合脑电生物反馈治疗对慢性精神分裂症社会功能康复的影响

Impact of Ziprasidone Joint EEG Biofeedback Treatment of Chronic Schizophrenia Patients and the Rehabilitation of Social Function

目的:探讨齐拉西酮联合脑电生物反馈治疗对慢性精神分裂症患者社会功能康复的影响。方法:将110例慢性精神分裂症患者随机分为齐拉西酮联合脑电生物反馈组55例(研究组,实际完成53例)和齐拉西酮组55例(对照组,实际完成52例),分别予齐拉西酮联合脑电生物反馈和齐拉西酮治疗8周。采用简明精神病量表(BPRS)、住院精神病患者社会功能评定量表(SSPI)评定。结果:第8周末研究组的BPRS总分的减分和BPRS减分率的增分较对照组显著(t1=-3.38,P<0.01;t2=2.54,P<0.05);研究组的显效率(64.15%)与对照组(42.31%)比较,差异有统计学意义(χ2=5.571,P=0.018)。研究组SSPI总分及各因子(除外日常生活能力)得分显著高于对照组(P<0.01或P<0.05)。结论:齐拉西酮联合脑电生物反馈治疗对慢性精神分裂症的疗效及社会功能缺陷的改善优于单用齐拉西酮。

Objective：To explore Ziprasidone joint EEG biofeedback treatment of chronic schizophrenia and its impact on the social function of the rehabilitation of patients.Methods：110patients with chronic schizophrenia were randomly divided into Ziprasidone combined EEG biofeedback group 55cases（53cases actually completed）and Ziprasidone group of 55cases（52cases actually completed）,Respectively to give Ziprasidone combined with EEG biofeedback and Ziprasidone treatment lasted eight weeks.Using Brief Psychiatric Rating Scale（BPRS）,the social function of psychiatric inpatients Rating Scale（SSPI）were evaluated.Results：8th week,the reduction rate of the study group of BPRS total score minus points and increase BPRS scores were higher,statistically significant（t1=-3.38,P〈0.01;t2=2.54,P〈0.05）;study group effective rate 64.15%and 42.31%in the control group was statistically significant difference（χ^2=5.571,P=0.018）.SSPI scores and factor scores（except for activities of daily living）of study group growth points were higher,statistically significant（P〈0.01 or P〈0.05）.Conclusion：Ziprasidone joint EEG biofeedback therapy to improve the efficacy of chronic schizophrenia and social dysfunction is better than a single treatment with Ziprasidone.